COPNZ Stock Overview
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 5/6 |
Past Performance | 1/6 |
Financial Health | 5/6 |
Dividends | 2/6 |
Cosmo Pharmaceuticals N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF71.00 |
52 Week High | CHF72.30 |
52 Week Low | CHF33.85 |
Beta | 1.19 |
1 Month Change | 7.25% |
3 Month Change | 17.16% |
1 Year Change | 29.80% |
3 Year Change | -22.49% |
5 Year Change | -24.39% |
Change since IPO | -54.19% |
Recent News & Updates
Recent updates
Shareholder Returns
COPNZ | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | 2.7% | -1.2% | -0.7% |
1Y | 29.8% | -5.0% | -1.8% |
Return vs Industry: COPNZ exceeded the UK Pharmaceuticals industry which returned -5.3% over the past year.
Return vs Market: COPNZ exceeded the UK Market which returned -2.4% over the past year.
Price Volatility
COPNZ volatility | |
---|---|
COPNZ Average Weekly Movement | 3.8% |
Pharmaceuticals Industry Average Movement | 8.7% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.5% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: COPNZ has not had significant price volatility in the past 3 months.
Volatility Over Time: COPNZ's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 319 | Alessandro Della Cha | www.cosmopharma.com |
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers’ diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX – IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies.
Cosmo Pharmaceuticals N.V. Fundamentals Summary
COPNZ fundamental statistics | |
---|---|
Market cap | CHF1.14b |
Earnings (TTM) | CHF1.11m |
Revenue (TTM) | CHF93.94m |
1,026x
P/E Ratio12.2x
P/S RatioIs COPNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
COPNZ income statement (TTM) | |
---|---|
Revenue | €96.72m |
Cost of Revenue | €39.34m |
Gross Profit | €57.38m |
Other Expenses | €56.24m |
Earnings | €1.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
Earnings per share (EPS) | 0.071 |
Gross Margin | 59.33% |
Net Profit Margin | 1.19% |
Debt/Equity Ratio | 0.1% |
How did COPNZ perform over the long term?
See historical performance and comparison